U.S. manufacturing is benefiting from reshoring incentives, refrigerant policy changes under the AIM Act, electric vehicle plant buildouts, and aerospace demand. Manufacturing contributes $2,961.4 billion to GDP in Q4 2025, and policy tailwinds are supporting capital investment. Chemours trades under $30 and shows strong recent performance, including a large year-over-year share rebound and a Q1 2026 adjusted EPS beat alongside revenue growth. The refrigerant transition is driving higher net sales and pricing for thermal and specialized solutions, while management uses proceeds from asset sales to reduce debt and reiterates EBITDA guidance. Key risks include net leverage and unresolved PFAS litigation. Rivian is also positioned around EV production and demand catalysts, with valuation reflecting uncertainty.
"At $25.26, Chemours sits well inside the under-$30 window, but the chart tells a recovery story: shares are up 115.28% year to date and 134.38% over the past year. Q1 2026 delivered adjusted EPS of $0.05 versus a -$0.05 consensus, a 225% beat on $1.381 billion in revenue. The analyst target sits at $25.78 with a forward P/E of 14."
"The bull case is the refrigerant transition. Thermal & Specialized Solutions net sales rose 22% to $568 million with Freon pricing up 67% in North America and Opteon up 12%, all driven by the AIM Act phasedown of legacy refrigerants. Management used $287 million in Kuan Yin sale proceeds to pay down €140 million in Euro term loans and reiterated FY2026 Adjusted EBITDA guidance of $800 to $900 million."
"The risk: net leverage of 4.9x and unresolved PFAS litigation remain real overhangs. Even so, with a domestic refrigerant manufacturing footprint, regulatory tailwinds, and active deleveraging, Chemours fits the renaissance template."
#us-manufacturing #specialty-chemicals #refrigerant-policy-aim-act #electric-vehicles #valuation-under-30
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]